NASDAQ:DARE Dare Bioscience (DARE) Stock Price, News & Analysis $0.93 -0.44 (-32.12%) Closing price 08/14/2026 04:00 PM EasternExtended Trading$0.90 -0.03 (-3.33%) As of 08/14/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Dare Bioscience Stock (NASDAQ:DARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dare Bioscience alerts:Sign Up Key Stats Today's Range$0.77▼$1.6150-Day Range$0.93▼$2.1752-Week Range$0.77▼$3.78Volume8.00 million shsAverage Volume502,329 shsMarket Capitalization$14.02 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use. In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market. Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.AI Generated. May Contain Errors. Read More Dare Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreDARE MarketRank™: Dare Bioscience scored higher than 46% of companies evaluated by MarketBeat, and ranked 537th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDare Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDare Bioscience has a consensus price target of $10.00, representing about 975.3% upside from its current price of $0.93.Amount of Analyst CoverageDare Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Dare Bioscience's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dare Bioscience are expected to grow in the coming year, from ($0.97) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dare Bioscience is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dare Bioscience is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDare Bioscience has a P/B Ratio of 4.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.81% of the float of Dare Bioscience has been sold short.Short Interest Ratio / Days to CoverDare Bioscience has a short interest ratio ("days to cover") of 3.25, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dare Bioscience has recently increased by 39.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDare Bioscience does not currently pay a dividend.Dividend GrowthDare Bioscience does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.63 News SentimentDare Bioscience has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Dare Bioscience this week, compared to 3 articles on an average week.Search Interest3 people have searched for DARE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows4 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dare Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders4.10% of the stock of Dare Bioscience is held by insiders.Percentage Held by Institutions6.70% of the stock of Dare Bioscience is held by institutions.Read more about Dare Bioscience's insider trading history. Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dare Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DARE Stock News HeadlinesDaré Bioscience, Inc.: Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy AdvancesAugust 14 at 12:59 AM | finanznachrichten.deDaré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesAugust 14 at 1:10 PM | markets.businessinsider.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing. | Porter & Company (Ad)Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesAugust 14 at 12:45 PM | globenewswire.comDaré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarterAugust 13 at 12:23 AM | seekingalpha.comDaré Bioscience, Inc. (DARE) Q2 2026 Earnings Call TranscriptAugust 13 at 11:00 PM | seekingalpha.comDaré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy AdvancesAugust 13 at 7:23 PM | markets.businessinsider.comDaré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy AdvancesAugust 13 at 4:01 PM | globenewswire.comSee More Headlines DARE Stock Analysis - Frequently Asked Questions How have DARE shares performed this year? Dare Bioscience's stock was trading at $1.93 at the start of the year. Since then, DARE stock has decreased by 51.8% and is now trading at $0.93. How were Dare Bioscience's earnings last quarter? Dare Bioscience, Inc. (NASDAQ:DARE) posted its quarterly earnings results on Thursday, August, 13th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. The biotechnology company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0 million. Dare Bioscience had a negative trailing twelve-month return on equity of 512.31% and a negative net margin of 803.80%. Read the conference call transcript. When did Dare Bioscience's stock split? Shares of Dare Bioscience reverse split on Monday, July 1st 2024.The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Dare Bioscience IPO? Dare Bioscience (DARE) raised $102 million in an initial public offering on Thursday, April 10th 2014. The company issued 8,500,000 shares at a price of $11.00-$13.00 per share. How do I buy shares of Dare Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dare Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dare Bioscience investors own include FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/13/2026Today8/15/2026Investor update8/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 3 weeks, DARE's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DARE CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees30Year Founded2006Price Target and Rating Average Price Target for Dare Bioscience$10.00 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+975.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.40 million Net Margins-803.80% Pretax Margin-1,038.08% Return on Equity-512.31% Return on Assets-36.20% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$1.03 million Price / Sales13.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book4.65Miscellaneous Outstanding Shares15,080,000Free Float14,462,000Market Cap$14.02 million OptionableNot Optionable Beta1.08 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:DARE) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThe Greatest Wealth Transfer Since the Internet Boom Just StartedWall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...Altimetry | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
